pyrroles has been researched along with Small Cell Lung Carcinoma in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (64.00) | 24.3611 |
| 2020's | 9 (36.00) | 2.80 |
| Authors | Studies |
|---|---|
| Das, M; Owonikoko, TK; Padda, SK; Weiss, J | 1 |
| Abraham, I; Chioda, M; Deniz, B; Huang, H; MacDonald, K; Moran, D; Onyekwere, U | 1 |
| Adler, S; Aljumaily, R; Antal, JM; Beck, JT; Boccia, RV; Bulat, I; Chiu, VK; Csoszi, T; Domine Gomez, M; Dragnev, KH; Hamm, JT; Hanna, W; Hart, LL; Hoyer, RJ; Hussein, MA; Lai, AY; Lowczak, A; Maglakelidze, M; Malik, RK; Morris, SR; Nikolinakos, P; Owonikoko, TK; Richards, DA; Roberts, PJ; Rocha Lima, CM; Sawrycki, P; Schuster, SR; Sorrentino, JA; Weiss, JM; Yang, Z | 1 |
| Aguirre, AJ; Almonte, C; Bonneau, R; Bulatovic, M; Castro, DM; Chen, T; Christensen, CL; Deng, J; Diskin, B; Donaghue, J; Dowling, CM; Dries, R; Freeman, GJ; Gray, NS; Hammerman, PS; Han, H; He, Z; Huang, Q; Jani, K; Kaelin, WG; Kersbergen, A; Kwiatkowski, N; Labbe, KE; Leggett, A; Li, F; Li, S; Miller, G; Oser, MG; Pan, Y; Papadopoulos, E; Pyon, V; Quinn, M; Rabin, AR; Ranieri, M; Rothenberg, E; Silver, H; Sundberg, B; Sutherland, KD; Sviderskiy, VO; Thakurdin, C; Velcheti, V; Wang, ES; Wong, KK; Yang, A; Yin, Y; Yuan, GC; Zhang, H; Zhang, T; Zhang, X | 1 |
| Abergel, RJ; An, DD; Ansoborlo, C; Gauny, SS; Karsunky, H; Lakes, AL; Liang, BH; McKnight, KD; Rees, JA | 1 |
| Deng, K; Ding, C; Hong, B; Li, H; Lin, WC; Liu, XL; Lui, VWY; Lv, XT; Shi, WH; Yin, YP | 1 |
| Andric, Z; Antal, JM; Daniel, D; Dragnev, KH; Goldschmidt, J; Gwaltney, C; Morris, SR; Pritchett, Y; Skaltsa, K; Weiss, J | 1 |
| Aschenbrenner, DS | 1 |
| Csőszi, T; Dómine Gómez, M; Horton, JK; Jaal, J; Kudaba, I; Malik, RK; Nikolov, K; Radosavljevic, D; Subramanian, J; Xiao, J | 1 |
| Anderson, I; Csőszi, T; Edenfield, W; Feinstein, TM; Ferrarotto, R; García-Campelo, MR; Johnson, JM; Kalmadi, S; Lammers, PE; Malik, RK; Medgyasszay, B; Morris, SR; Pritchett, Y; Sanchez-Hernandez, A | 1 |
| Yaqub, F | 1 |
| Albert, I; Ao-Baslock, A; Berger, MS; Blakely, LJ; Kazarnowicz, A; Kovacs, P; Langer, CJ; Moezi, MM; Pajkos, G; Pathak, AK; Ross, HJ; Schnyder, J; Schreeder, MT; Somfay, A; Zatloukal, P | 1 |
| Abdullaev, Z; Beadling, C; Berman, A; Carter, CA; Corless, CL; Doyle, A; Giaccone, G; Guha, U; Kelly, R; Killian, K; Lau, CC; Liewehr, DJ; Lopez-Chavez, A; Meltzer, PS; Morrow, B; Pack, S; Raffeld, M; Rajan, A; Sandler, A; Steinberg, SM; Szabo, E; Thomas, A; Wang, Y; Warrick, A; Xi, L | 1 |
| Baggstrom, M; Bogart, J; Crawford, J; Graziano, SL; Gu, L; Masters, GA; Miller, AA; Otterson, GA; Pang, HH; Ready, NE; Thomas, SP; Vokes, EE | 1 |
| Tanday, S | 1 |
| Leighl, NB | 1 |
| Abdelraouf, F; Baas, P; Hasan, B; Menis, J; O'Brien, M; Popat, S; Smit, E; Surmont, VF; van Meerbeeck, JP | 1 |
| Bogart, JA; Crawford, J; Gu, L; Pang, HH; Ready, NE; Salama, JK; Schild, SE; Vokes, EE; Wang, X | 1 |
| Berger, M; Blackhall, F; Cummings, J; Dean, EJ; Dive, C; Ranson, M; Roulston, A | 1 |
| Daignault, S; Dy, GK; Gadgeel, SM; Kalemkerian, GP; Ramnath, N; Schneider, BJ; Wozniak, AJ | 1 |
| Berger, MS; Blakely, J; Chiappori, AA; Chu, QS; Moezi, MM; Ross, HJ; Salgia, R; Schnyder, J; Schreeder, MT; Stephenson, JJ; Subramaniam, DS | 1 |
| Burris, HA; Eakle, JF; Greco, FA; Hainsworth, JD; Lubiner, ET; Quinn, R; Rubin, MS; Shipley, D; Spigel, DR; Thompson, DS | 1 |
| Barck, KH; Cao, TC; Carano, RA; Cheng, JH; Couto, SS; Eastham-Anderson, J; Ferrara, N; Foreman, O; Forrest, WF; Hamilton, P; Ho, CC; Johnson, L; Jubb, AM; Kasman, I; Lima, A; Long, JE; McNutt, A; Molina, R; Nannini, MA; Reslan, HB; Singh, M | 1 |
| Han, JH; Han, JY; Kim, HJ; Kim, HT; Kim, HY; Kwak, MH; Lee, JS; Lee, YJ; Lim, KY; Yun, T | 1 |
1 review(s) available for pyrroles and Small Cell Lung Carcinoma
| Article | Year |
|---|---|
Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Pyrimidines; Pyrroles; Small Cell Lung Carcinoma | 2021 |
13 trial(s) available for pyrroles and Small Cell Lung Carcinoma
| Article | Year |
|---|---|
Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy.
Topics: Antineoplastic Agents; Humans; Lung Neoplasms; Pyrimidines; Pyrroles; Quality of Life; Small Cell Lung Carcinoma | 2021 |
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cisplatin; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Double-Blind Method; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Myeloid Cells; Paclitaxel; Prognosis; Pyrimidines; Pyrroles; Small Cell Lung Carcinoma; Survival Rate; Tissue Distribution | 2019 |
Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
Topics: Aged; Cytoprotection; Double-Blind Method; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Myeloid Cells; Prognosis; Prospective Studies; Pyrimidines; Pyrroles; Small Cell Lung Carcinoma | 2021 |
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
Topics: Antineoplastic Agents; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Neutropenia; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Small Cell Lung Carcinoma | 2021 |
Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Comorbidity; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult | 2015 |
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2015 |
Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Patient Selection; Positron-Emission Tomography; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrroles; Sample Size; Small Cell Lung Carcinoma; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cranial Irradiation; Disease-Free Survival; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Placebos; Pyrroles; Retrospective Studies; Small Cell Lung Carcinoma; Sunitinib | 2016 |
Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Early Termination of Clinical Trials; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Patient Dropouts; Platinum; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2011 |
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System; Drug Administration Schedule; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Small Cell Lung Carcinoma | 2012 |
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease Progression; Female; Humans; Indoles; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2012 |
A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Asthenia; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Thrombocytopenia; Treatment Outcome | 2013 |
11 other study(ies) available for pyrroles and Small Cell Lung Carcinoma
| Article | Year |
|---|---|
CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemokine CXCL9; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; DNA Damage; Female; Genomic Instability; Humans; Immune System; Inflammation; Interferon-gamma; Lung Neoplasms; Male; Mice; Micronucleus Tests; Programmed Cell Death 1 Receptor; Pyrazoles; Pyrroles; Signal Transduction; Small Cell Lung Carcinoma; Tumor Necrosis Factor-alpha | 2020 |
Evaluating
Topics: Actinium; Alpha Particles; Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Benzodiazepines; Beta Particles; Female; HEK293 Cells; Humans; Immunoconjugates; Immunoglobulin G; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Lutetium; Maximum Tolerated Dose; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Pyrroles; Radioisotopes; Small Cell Lung Carcinoma; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Cell Line, Tumor; Drug Synergism; Forkhead Box Protein M1; HEK293 Cells; Humans; Indoles; Lung Neoplasms; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Oligopeptides; Proteasome Inhibitors; Pyrroles; Small Cell Lung Carcinoma; Up-Regulation; Xenograft Model Antitumor Assays | 2021 |
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
Topics: Antineoplastic Agents; Bone Marrow; Clinical Trials, Phase II as Topic; Double-Blind Method; Humans; Patient Reported Outcome Measures; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan | 2021 |
New Drug Protects Against Myelosuppression Secondary to Lung Cancer Chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow; Dose-Response Relationship, Drug; Humans; Leukopenia; Lung Neoplasms; Neutropenia; Pyrimidines; Pyrroles; Small Cell Lung Carcinoma | 2021 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
Sunitinib benefits patients with small-cell lung cancer.
Topics: Humans; Indoles; Pyrroles; Small Cell Lung Carcinoma; Sunitinib | 2015 |
Sunitinib: the next advance in small-cell lung cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indoles; Lung Neoplasms; Male; Pyrroles; Small Cell Lung Carcinoma | 2015 |
ADC Shows Effectiveness in SCLC.
Topics: Antibodies, Monoclonal; Benzodiazepines; Humans; Immunoconjugates; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Pyrroles; Retreatment; Small Cell Lung Carcinoma; Treatment Outcome | 2015 |
Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Chemical Analysis; Calibration; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clinical Trials, Phase I as Topic; Drug Synergism; Etoposide; Humans; Indoles; Lung Neoplasms; Prognosis; Pyrroles; Small Cell Lung Carcinoma | 2011 |
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Anti-Idiotypic; Disease Models, Animal; Drug Therapy, Combination; Genetic Engineering; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |